Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06706973

Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer

Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Head and Neck Cancer Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

European Institute of oncology

Milan, MI, 20141, Italy

Location status: Recruiting

About this study

Head and neck cancer (HNC) is a highly heterogeneous disease, involving diverse anatomical sites including oral cavity, larynx and oropharynx. HNC risk factors include tobacco smoking and alcohol consumption and, especially for the subtype of oropharyngeal cancers (OPC), human papillomavirus (HPV) infection

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Age: Adults aged ≥ 18 years diagnosed with HNC

  • Sex: Both male and female
  • Human papilloma virus (HPV) test: Both positive and negative.
  • Tumor: primary tumors, treatment naïve, squamous cell carcinoma
  • Cancer stage: I-IV
  • Anatomic location: oral cavity, larynx, oropharynx
  • Tumor fragments not required for diagnostics

Exclusion criteria

  • Previous radiotherapy, chemotherapy or immunotherapy for HNC
  • Unable to provide written informed consent

Treatment and study plan

Primary outcomes

  1. PROFILING AND TARGETING EPIGENETIC MARKS TO IMPROVE DIAGNOSIS AND THERAPEUTIC APPROACHES IN HEAD AND NECK CANCER

    Time frame: 2 years

    define and fully characterize histone Post-Translational Modifications (hPTMs) and differentially expressed chromatin modifiers in HPV+ vs HPV- HNC through cutting-edge methodologies

Study contacts

Contact information is provided by the study sponsor or research team.

Susanna Chiocca, Doctor

CONTACT

[email protected]

00390257488835

francesca lombardi, dr

CONTACT

[email protected]

0039-02-57489425

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Collaborators

  • Associazione Italiana per la Ricerca sul Cancro

Registry information

Acronym: AIRC-Chiocca

Important dates

Study start
2024
Primary completion
2030
Study completion
2030
First posted
Nov 27, 2024
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.